FKRP and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan: Gene therapy [55, 71, 73, 77], estrogen receptor modulators [79], and exogenous ribitol supplementation [9] improve muscle structure in FKRP-associated dystroglycanopathy models.